Literature DB >> 9009250

Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes.

D D Ma1, A Q Wei.   

Abstract

The ability of pH-sensitive liposomes and immunoliposomes to deliver synthetic antisense oligonucleotides (oligos) into human myeloid and lymphoid leukaemia cells was examined. The cellular uptake of an 18mer anti-myb oligonucleotide encapsulated in liposomes was from three- to five-fold higher than that of 32P-oligos alone. In addition, anti-CD32 or anti-CD2 immunoliposomes improved the delivery of oligos to leukaemic cells carrying the appropriate receptor for the specific antibody-linked immunoliposome. The uptake of oligos was twice that of the liposome or non-specific immunoliposome encapsulated oligos. These findings support the use of liposomes or immunoliposomes to deliver antisense oligos into human leukaemic cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9009250     DOI: 10.1016/s0145-2126(96)00062-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Intracellular compartmentalization of DNA fragments in cultured airway epithelial cells mediated by cationic lipids.

Authors:  A R Holmes; A F Dohrman; A R Ellison; K K Goncz; D C Gruenert
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 2.  Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.

Authors:  Amjad Ali Khan; Khaled S Allemailem; Saleh A Almatroodi; Ahmed Almatroudi; Arshad Husain Rahmani
Journal:  3 Biotech       Date:  2020-03-10       Impact factor: 2.406

Review 3.  Delivery of oligonucleotides with lipid nanoparticles.

Authors:  Yuhua Wang; Lei Miao; Andrew Satterlee; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2015-02-27       Impact factor: 15.470

4.  Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.

Authors:  E G Marcusson; B Bhat; M Manoharan; C F Bennett; N M Dean
Journal:  Nucleic Acids Res       Date:  1998-04-15       Impact factor: 16.971

5.  Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.

Authors:  R Z Yu; R S Geary; J M Leeds; T Watanabe; J R Fitchett; J E Matson; R Mehta; G R Hardee; M V Templin; K Huang; M S Newman; Y Quinn; P Uster; G Zhu; P K Working; M Horner; J Nelson; A A Levin
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

6.  Antisense imaging of colon cancer-bearing nude mice with liposome-entrapped 99m-technetium-labeled antisense oligonucleotides of c-myc mRNA.

Authors:  Jian-Guo Zheng; Tian-Zhi Tan
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

Review 7.  Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

Authors:  Alexander Batista-Duharte; Luis Sendra; Maria José Herrero; Damiana Téllez-Martínez; Iracilda Zeppone Carlos; Salvador Francisco Aliño
Journal:  Biomolecules       Date:  2020-02-17

Review 8.  Innovations in oligonucleotide drug delivery.

Authors:  Melanie A Lysik; Susanna Wu-Pong
Journal:  J Pharm Sci       Date:  2003-08       Impact factor: 3.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.